Information from Industry - Sponsored Supplement
Fourth Study to Show Consistent Benefit of Highly Purified Eicosapentaenoic Acid on Cardiovascular Outcomes: Results From RESPECT-EPA
Developed under the direction and sponsorship of Amarin Pharma, Inc. This content was prepared by the specialized content division of FMC of Cardiology News.
January 3, 2023|Cardiology
In this supplement to Cardiology News, John R. Nelson, MD, FACC, FNLA, FASNC, and Matthew J. Budoff, MD, discuss results from RESPECT-EPA and the existing evidence that purified eicosapentaenoic acid significantly reduces residual CV risk in patients with CVD.